The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
(1976) · Medical Entomology and Zoology · Cited by 8,899
Varni, J. W., Seid, M., & Kurtin, P. S. (2001) · Medical Care · doi:10.1097/00005650-200108000-00006 · Cited by 5,131
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citation
Cited by
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0100-y · Cited by 987
Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.10.013 · Cited by 848
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
The Status of Irritability in Psychiatry: A Conceptual and Quantitative Review
Vidal-Ribas, P., Brotman, M. A., Valdivieso, I., Leibenluft, E., & Stringaris, A. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.04.014 · Cited by 471
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
“Significant improvements on the ABC-Stereotypy scale and CY-BOCS were reported from a large study in children and adolescents with ASD (Marcus et al., 2009) (evidence level IIa) (down-graded because this was not the primary outcome measure).”
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S.-J., Spanos, M., Chandrasekhar, T., Trelles, M. D. P., Rockhill, C. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103583 · Cited by 298
A randomized controlled pilot trial of oral N-acetylcysteine in children with autism
Hardan, A. Y., Fung, L. K., Libove, R. A., Obukhanych, T. V., Nair, S., Herzenberg, L. A., Frazier, T. W., & Tirouvanziam, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.014 · Cited by 293
Fung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294
Marotta, R., Risoleo, M. C., Messina, G., Parisi, L., Carotenuto, M., Vetri, L., & Roccella, M. (2020) · Brain Sciences · doi:10.3390/brainsci10030163 · Cited by 279
“Only the dopamine receptor blockers (risperidone and aripiprazole) are EMA/FDA-approved for the treatment of irritability, and they have also been shown to be effective in treating ASD repetitive behaviors [84,85].”
BackgroundValidity of the Aberrant Behavior Checklist in Children with Autism Spectrum Disorder
Kaat, A. J., Lecavalier, L., & Aman, M. G. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1970-0 · Cited by 271
Self-citationAggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Maayan, L., & Correll, C. U. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0015 · Cited by 252
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis
Sukhodolsky, D. G., Bloch, M. H., Panza, K. E., & Reichow, B. (2013) · Pediatrics · doi:10.1542/peds.2013-1193 · Cited by 234
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171
Mazefsky, C. A., Yu, L., White, S. W., Siegel, M., & Pilkonis, P. A. (2018) · Autism Research · doi:10.1002/aur.1947 · Cited by 169
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“Other treatments, including the atypical antipsychotics risperidone and aripripazole, can effectively target comorbid irritability, agitation, and aggression (Marcus et al, 2009; McCracken et al, 2002).”
BackgroundAnagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1232 · Cited by 123
“Nervous system disorders Dizziness 2 (7) 1 (3) .”
BackgroundSelf-citationFrazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0057 · Cited by 113
Rodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
Munesue, T., Nakamura, H., Kikuchi, M., Miura, Y., Takeuchi, N., Anme, T., Nanba, E., Adachi, K., Tsubouchi, K., Sai, Y., et al. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00002 · Cited by 84
Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Aman, M. G. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0121 · Cited by 82
“Dis-continuation rates due to lack of efficacy were also low in the double-blind studies; no aripiprazole-treated subjects in the fixed-dose study (Marcus et al. 2009) and 2.1% of aripiprazole-treated subjects in the flexible-dose study discontinued treatment due to lack of efficacy (Owen et al. 2009).”
InfluentialSelf-citationPsychopharmacology in autism: an update
Canitano, R., & Scandurra, V. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.015 · Cited by 79
Masi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
Blankenship, K., Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010) · Pediatric Health · doi:10.2217/phe.10.45 · Cited by 75
“In three of the studies discussed above, the prolactin levels were recorded at baseline and at the end of the study [13,14,16].”
BackgroundInfluentialImmunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
“The compound is a partial D2 and 5-HT1A agonist, and a 5-HT2A antagonist (Burris et al. 2002; Jordan et al. 2002 ).”
BackgroundAripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.04.001 · Cited by 65
“In the fixed-dose study, all aripiprazole doses (5, 10, or 15 mg/day) were associated with significantly greater improvement in mean ABC-I and CGI-I scores compared to a placebo.(27) Discontinuation rates from adverse effects of aripiprazole ranged from 7.”
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Bennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders
Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.487860 · Cited by 36
Review of interventions for the management of anxiety symptoms in children with ASD
Delli, C. K. S., Polychronopoulou, S. A., Kolaitis, G. A., & Antoniou, A. S. G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.10.023 · Cited by 30
Psychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Preckel, K., Kanske, P., Singer, T., Paulus, F. M., & Krach, S. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1036-x · Cited by 25
Improving the Prediction of Response to Therapy in Autism
Bent, S., & Hendren, R. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.011 · Cited by 25
“A second atypical antipsychotic, aripiprazole, was approved in late 2009 for the same indication (irritability) in children with ASD, based on the results from two 8-week randomized, placebo-controlled trials in 98 and 218 patients.(6,7) In the larger study, irritability improved 14% to 21% over 8 weeks, but side effe…”
BackgroundPsychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder
Handen, B. L., Taylor, J., & Tumuluru, R. (2011) · ijamh · doi:10.1515/ijamh.2011.039 · Cited by 26
Psychotropic medications in autism: practical considerations for parents
Williamson, E. D., & Martin, A. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1144-2 · Cited by 20
Murphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
“Although there is limited evidence to guide psychotropic medication use in the ASD population, two drugs have shown efficacy for the alleviation of behavioural symptoms in children and adolescents with autistic disorder: risperidone (Risperdal®, Janssen-Cilag Ltd) 292,293 and aripiprazole (Abilify®; Otsuka Pharmaceuti…”
BackgroundManaging disruptive behaviour in autism-spectrum disorder with guanfacine
Propper, L. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180039 · Cited by 12
Curran, M. P. (2011) · CNS Drugs · doi:10.2165/11208280-000000000-00000 · Cited by 10
“multicenter, phase III trials that investigated the efficacy of aripiprazole (ARI) for the treatment of irritability associated with autistic disorder([15,16])”
BackgroundMethodInfluential
Metadata
- Authors
- Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 48
- Issue
- 11
- Pages
- 1110-1119
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2018998808
- Cited by
- 566
- References
- 25
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.